In one report, a slightly higher concentration of liraglutide accelerated breast cancer progression in vitro and in vivo through the NOX4/ROS/VEGF signaling pathway after activation the GLP-1 receptor [97]. The gene discussed is VEGFA; the disease is breast carcinoma.